ofloxacin has been researched along with Gram-Positive Bacterial Infections in 54 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Gram-Positive Bacterial Infections: Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis." | 9.12 | A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. ( Anon, J; Kahn, J; Khashab, M; Paglia, M; Poole, M; Xiang, J, 2006) |
| "A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil." | 9.09 | Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999) |
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 9.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| "The purpose of this study was to assess the clinical efficacy of high-dose levofloxacin plus rifampicin in the empirical treatment of non-tuberculous spondylodiscitis in an epidemiological context of low incidence of staphylococcal fluoroquinolone resistance." | 7.75 | Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. ( Crapis, M; Cristini, F; Furlanut, M; Negri, C; Pavan, F; Pea, F; Scudeller, L; Viale, P; Zamparini, E; Zuiani, C, 2009) |
| "Thirty cirrhotic patients with spontaneous bacterial peritonitis were assigned to receive either intravenous (1 g/12 h) cefotaxime for 7 days (n=17) or intravenous (200 mg/12 h) ofloxacin for 2 days followed by oral (200 mg/12 h) ofloxacin for 5 days (n=13)." | 7.72 | Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis. ( Aslan, SL; Buyraç, Z; Colakoğlu, O; Sözmen, B; Taşkiran, B; Unsal, B, 2004) |
| "Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis." | 5.12 | A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. ( Anon, J; Kahn, J; Khashab, M; Paglia, M; Poole, M; Xiang, J, 2006) |
| "The objective of this multicenter, randomized, controlled, parallel group trial was to evaluate the efficacy of levofloxacin 250 mg oral, once daily (LVFX), placebo one tablet oral once daily (Placebo [P] group) and ciprofloxacin (CPFX) 500 mg oral, twice daily (single blind), prophylaxis in preventing bacteriuria (> or = 10(3) CFU/ml) in post-surgical catheterized patients." | 5.12 | A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. ( Drago, L; Esposito, S; Leone, S; Marchetti, F; Marvaso, A; Noviello, S, 2006) |
| "A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil." | 5.09 | Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999) |
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 5.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| "We examined Enterococcus faecalis strains clinically isolated from 100 patients with urinary tract infections (UTIs) for their susceptibility to levofloxacin (LVX) by measuring the MIC and investigated amino acid mutations by direct DNA sequencing, which were then correlated with LVX resistance." | 3.77 | Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections. ( Arakawa, S; Fujisawa, M; Kawabata, M; Matsumoto, M; Nakano, Y; Shigemura, K; Shirakawa, T; Tanaka, K; Yasufuku, T, 2011) |
| "The purpose of this study was to assess the clinical efficacy of high-dose levofloxacin plus rifampicin in the empirical treatment of non-tuberculous spondylodiscitis in an epidemiological context of low incidence of staphylococcal fluoroquinolone resistance." | 3.75 | Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. ( Crapis, M; Cristini, F; Furlanut, M; Negri, C; Pavan, F; Pea, F; Scudeller, L; Viale, P; Zamparini, E; Zuiani, C, 2009) |
| "3% gatifloxacin ophthalmic solution in preventing bacterial endophthalmitis in rabbits." | 3.74 | Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. ( Kozai, S; Ohashi, Y; Sakaki, H; Suzuki, T; Tajika, T; Wada, T, 2008) |
| "Thirty cirrhotic patients with spontaneous bacterial peritonitis were assigned to receive either intravenous (1 g/12 h) cefotaxime for 7 days (n=17) or intravenous (200 mg/12 h) ofloxacin for 2 days followed by oral (200 mg/12 h) ofloxacin for 5 days (n=13)." | 3.72 | Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis. ( Aslan, SL; Buyraç, Z; Colakoğlu, O; Sözmen, B; Taşkiran, B; Unsal, B, 2004) |
| "We report a case of bacteremia due to Abiotrophia species in a patient with neutropenic fever and cancer who was receiving levofloxacin prophylaxis, followed by empirical therapy with cefepime; the organism was resistant to both antibiotics." | 3.71 | Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. ( Crawford, S; Jorgensen, JH; McElmeel, ML; Murray, CK; Walter, EA, 2001) |
| "Febrile neutropenia is an expected complication during treatment of aggressive hematological malignancies and hematopoietic cell transplantation." | 2.73 | The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. ( Craig, M; Cumpston, AD; Devetten, MP; Ericson, SG; Hobbs, GR; Sarwari, AR, 2007) |
| " Pharmacokinetic parameters of levofloxacin, including the maximum serum concentration (C(max)), time to C(max) (T(max)), area under the concentration-time curve (AUC), volume of distribution at steady state (V(ss)/F) and clearance (CL/F) were not statistically different at first dose and during neutropenia." | 2.71 | Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. ( Dijstelbloem, Y; Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, DJ; van Winkelhoff, AJ; Vandenbroucke-Grauls, CM, 2004) |
| "Both cancer centers differed in prophylactic antibiotic policies." | 2.69 | Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998) |
| " three times daily with dosage adjustment according to renal function and body weight (group 2)." | 2.67 | Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. ( Maiche, AG; Teerenhovi, L, 1991) |
| "Patients who are treated for acute leukemia should be offered prophylaxis with ciprofloxacin or levofloxacin." | 2.43 | Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. ( Bucaneve, G; Cullen, M; Fraser, A; Gafter-Gvili, A; Kern, WV; Leibovici, L; Paul, M, 2006) |
| "Levofloxacin is a fluoroquinolone antibiotic and is the optical S-(-) isomer of the racemic drug substance ofloxacin." | 2.40 | The clinical pharmacokinetics of levofloxacin. ( Chow, AT; Fish, DN, 1997) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| "Paronychia is a well-known, but difficult to treat cutaneous toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy." | 1.36 | Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. ( Eames, T; Grabein, B; Kroth, J; Wollenberg, A, 2010) |
| " The aim of this study was to compare the therapeutic efficacy of quinupristin-dalfopristin (QD) alone, or in combination with gentamicin (G), teicoplanin (T), imipenem (I) or levofloxacin (L) against a strain of multidrug-resistant E." | 1.33 | [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium]. ( Gómez Gómez, J; López Fornás, F; Lorente Salinas, I; Martínez García, F; Pérez Salmerón, J; Roldán Conesa, D; Ruiz Gómez, J; Segovia Hernández, M; Valdés Chávarri, M, 2006) |
| "Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp." | 1.30 | Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. ( Barry, AL; Brown, SD; Fuchs, PC, 1999) |
| "Sparfloxacin was more active than both ciprofloxacin and ofloxacin against all the isolates tested." | 1.29 | In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci. ( Amsterdam, D; Beam, TR; Gorzynski, EA; Mandell, LA; Rotstein, C, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 15 (27.78) | 18.2507 |
| 2000's | 26 (48.15) | 29.6817 |
| 2010's | 11 (20.37) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, L | 1 |
| Huang, H | 1 |
| Wu, Z | 1 |
| Liu, P | 1 |
| Huang, J | 1 |
| Chen, Y | 1 |
| Romero-Trevejo, JL | 1 |
| Somavilla-Lupiáñez, J | 1 |
| Saidane, O | 1 |
| Mahmoud, I | 1 |
| Saadi, F | 1 |
| Souayah, A | 1 |
| Zouari, R | 1 |
| Rasool, MH | 1 |
| Siddique, AB | 1 |
| Saqalein, M | 1 |
| Asghar, MJ | 1 |
| Zahoor, MA | 1 |
| Aslam, B | 1 |
| Shafiq, HB | 1 |
| Nisar, MA | 1 |
| Tsuchiya, Y | 1 |
| Kobayakawa, S | 1 |
| Tsuji, A | 1 |
| Tochikubo, T | 1 |
| Viale, P | 1 |
| Furlanut, M | 1 |
| Scudeller, L | 1 |
| Pavan, F | 1 |
| Negri, C | 1 |
| Crapis, M | 1 |
| Zamparini, E | 1 |
| Zuiani, C | 1 |
| Cristini, F | 1 |
| Pea, F | 1 |
| Reddy, AK | 1 |
| Garg, P | 1 |
| Alam, MR | 1 |
| Gopinathan, U | 1 |
| Sharma, S | 1 |
| Krishnaiah, S | 1 |
| Gupta, A | 1 |
| Swaroop, C | 1 |
| Agarwala, S | 1 |
| Pandey, RM | 1 |
| Bakhshi, S | 1 |
| Eames, T | 1 |
| Grabein, B | 1 |
| Kroth, J | 1 |
| Wollenberg, A | 1 |
| Kim, HS | 1 |
| Park, DW | 1 |
| Youn, YK | 1 |
| Jo, YM | 1 |
| Kim, JY | 1 |
| Song, JY | 1 |
| Sohn, JW | 1 |
| Cheong, HJ | 1 |
| Kim, WJ | 1 |
| Kim, MJ | 1 |
| Choi, WS | 1 |
| Cai, T | 1 |
| Mazzoli, S | 1 |
| Meacci, F | 1 |
| Boddi, V | 1 |
| Mondaini, N | 1 |
| Malossini, G | 1 |
| Bartoletti, R | 1 |
| Yasufuku, T | 1 |
| Shigemura, K | 1 |
| Shirakawa, T | 1 |
| Matsumoto, M | 1 |
| Nakano, Y | 1 |
| Tanaka, K | 1 |
| Arakawa, S | 1 |
| Kawabata, M | 1 |
| Fujisawa, M | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Parra-Riffo, H | 1 |
| Lemus-Peñaloza, J | 1 |
| Tasaka, Y | 1 |
| Suzuki, T | 2 |
| Kawasaki, S | 1 |
| Uda, T | 1 |
| Mito, T | 1 |
| Uno, T | 1 |
| Ohashi, Y | 2 |
| Matoba, AY | 1 |
| Timmers, GJ | 1 |
| Dijstelbloem, Y | 1 |
| Simoons-Smit, AM | 1 |
| van Winkelhoff, AJ | 1 |
| Touw, DJ | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Huijgens, PC | 1 |
| Taşkiran, B | 1 |
| Colakoğlu, O | 1 |
| Sözmen, B | 1 |
| Unsal, B | 1 |
| Aslan, SL | 1 |
| Buyraç, Z | 1 |
| Gopalachar, A | 1 |
| Akins, RL | 1 |
| Davis, WR | 1 |
| Siddiqui, AA | 1 |
| Ma, ES | 1 |
| Wong, CL | 1 |
| Lai, KT | 1 |
| Chan, EC | 1 |
| Yam, WC | 1 |
| Chan, AC | 1 |
| Pust, RA | 1 |
| Ackenheil-Koppe, HR | 1 |
| Gilbert, P | 1 |
| Weidner, W | 1 |
| Poole, M | 1 |
| Anon, J | 1 |
| Paglia, M | 1 |
| Xiang, J | 1 |
| Khashab, M | 1 |
| Kahn, J | 1 |
| Leibovici, L | 1 |
| Paul, M | 1 |
| Cullen, M | 1 |
| Bucaneve, G | 1 |
| Gafter-Gvili, A | 1 |
| Fraser, A | 1 |
| Kern, WV | 1 |
| Pérez Salmerón, J | 1 |
| Martínez García, F | 1 |
| Roldán Conesa, D | 1 |
| Lorente Salinas, I | 1 |
| López Fornás, F | 1 |
| Ruiz Gómez, J | 1 |
| Gómez Gómez, J | 1 |
| Segovia Hernández, M | 1 |
| Valdés Chávarri, M | 1 |
| Esposito, S | 2 |
| Noviello, S | 2 |
| Leone, S | 2 |
| Marvaso, A | 1 |
| Drago, L | 1 |
| Marchetti, F | 1 |
| Craig, M | 1 |
| Cumpston, AD | 1 |
| Hobbs, GR | 1 |
| Devetten, MP | 1 |
| Sarwari, AR | 1 |
| Ericson, SG | 1 |
| Ianniello, F | 1 |
| Kailasanathan, A | 1 |
| Anderson, DF | 1 |
| Altiparmak, UE | 1 |
| Ozer, PA | 1 |
| Ozkuyumcu, C | 1 |
| Us, AD | 1 |
| Aslan, BS | 1 |
| Duman, S | 1 |
| Munir, WM | 1 |
| El Mallah, MK | 1 |
| Janda, WM | 1 |
| Tu, EY | 1 |
| Wada, T | 1 |
| Kozai, S | 1 |
| Tajika, T | 1 |
| Sakaki, H | 1 |
| Savitskaia, KI | 1 |
| Tsar'kova, LN | 1 |
| Shanina, AG | 1 |
| Nasonov, VN | 1 |
| Solodilova, OE | 1 |
| Rusanova, EV | 1 |
| Pfaller, MA | 1 |
| Barry, AL | 2 |
| Fuchs, PC | 2 |
| Rotstein, C | 2 |
| Amsterdam, D | 2 |
| Beam, TR | 1 |
| Mandell, LA | 2 |
| Gorzynski, EA | 1 |
| Fish, DN | 1 |
| Chow, AT | 1 |
| Tsuchimori, N | 1 |
| Yamazaki, T | 1 |
| Okonogi, K | 1 |
| Krupova, I | 1 |
| Kaiserova, E | 1 |
| Foltinova, A | 1 |
| Kovacicova, G | 1 |
| Kiskova, M | 1 |
| Krchnakova, A | 1 |
| Kunova, A | 1 |
| Trupl, J | 1 |
| West, D | 1 |
| Krcmery, V | 2 |
| Colsky, AS | 1 |
| Kirsner, RS | 1 |
| Kerdel, FA | 1 |
| Isenberg, HD | 1 |
| Alperstein, P | 1 |
| France, K | 1 |
| Dhawan, VK | 1 |
| Nachum, R | 1 |
| Bhat, N | 1 |
| Tolbert, L | 1 |
| Agrawal, M | 1 |
| Krupova, Y | 1 |
| Novotny, J | 1 |
| Sabo, A | 1 |
| Mateicka, F | 1 |
| von Eiff, C | 1 |
| Peters, G | 1 |
| Shah, PM | 1 |
| Maesen, FP | 1 |
| Dolmann, A | 1 |
| Vetter, N | 1 |
| Fiss, E | 1 |
| Wesch, R | 1 |
| Brown, SD | 1 |
| Geddes, A | 1 |
| Thaler, M | 1 |
| Schonwald, S | 1 |
| Härkönen, M | 1 |
| Jacobs, F | 1 |
| Nowotny, I | 1 |
| Hardy, D | 1 |
| Blondeau, JM | 1 |
| Laskowski, R | 1 |
| Bjarnason, J | 1 |
| Stewart, C | 1 |
| Alexandrakis, G | 1 |
| Alfonso, EC | 1 |
| Miller, D | 1 |
| Manzella, J | 1 |
| Benenson, R | 1 |
| Pellerin, G | 1 |
| Kellogg, J | 1 |
| Bell, T | 1 |
| Robertson, M | 1 |
| Pope, D | 1 |
| Murray, CK | 1 |
| Walter, EA | 1 |
| Crawford, S | 1 |
| McElmeel, ML | 1 |
| Jorgensen, JH | 1 |
| Budanov, SV | 1 |
| Smirnova, LB | 1 |
| Ho, PL | 1 |
| Ng, TK | 1 |
| Yung, RW | 1 |
| Que, TL | 1 |
| Yip, EK | 1 |
| Tse, CW | 1 |
| Yuen, KY | 1 |
| Kuriyama, T | 1 |
| Karasawa, T | 1 |
| Nakagawa, K | 1 |
| Yamamoto, E | 1 |
| Nakamura, S | 1 |
| Maiche, AG | 1 |
| Teerenhovi, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Contribution of Fast Molecular Bacterial Identification by Real-time PCR in Managing of Postoperative Acute Endophthalmitis[NCT02850653] | 150 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ofloxacin and Gram-Positive Bacterial Infections
| Article | Year |
|---|---|
Severe levofloxacin-induced hypoglycaemia: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Drug Therapy, Combination; Enterococcus; G | 2012 |
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Topics: Acute Disease; Antibiotic Prophylaxis; Antineoplastic Agents; Bone Marrow Transplantation; Ciproflox | 2006 |
The clinical pharmacokinetics of levofloxacin.
Topics: Anti-Infective Agents; Clinical Trials, Phase III as Topic; Drug Interactions; Gram-Negative Bacteri | 1997 |
[Levofloxacin (Tavanic)--a novel quinolone of the III generation. Antimicrobial activity, pharmacokinetics, clinical significance].
Topics: Anti-Infective Agents; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxa | 2001 |
10 trials available for ofloxacin and Gram-Positive Bacterial Infections
| Article | Year |
|---|---|
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
Topics: Administration, Oral; Adolescent; Ambulatory Care; Amikacin; Amoxicillin-Potassium Clavulanate Combi | 2009 |
Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Digestive System; Drug Resistance, Bacteri | 2004 |
A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2006 |
A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; | 2006 |
The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Drug Administration Schedule; Drug Resist | 2007 |
[Use of ofloxacin in the treatment of infections of the lower respiratory tract].
Topics: Adolescent; Adult; Asthma; Bronchitis; Chronic Disease; Female; Gram-Negative Bacterial Infections; | 1994 |
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A | 1998 |
Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chron | 1999 |
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Cilastatin; Cilastati | 1999 |
Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.
Topics: Administration, Oral; Cefotaxime; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacterial | 1991 |
40 other studies available for ofloxacin and Gram-Positive Bacterial Infections
| Article | Year |
|---|---|
Chronic suppurative otitis media due to Streptomyces cacaoi, the second case report in human infection.
Topics: Anti-Bacterial Agents; China; Female; Gram-Positive Bacterial Infections; Humans; Middle Aged; Oflox | 2020 |
Canaliculitis due to Gemella haemolysans in a single isolate.
Topics: Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Canaliculitis; Combined Modality T | 2018 |
[Spondylodiscitis and Lactococcus cremoris endocarditis].
Topics: Aged; Animals; Anti-Bacterial Agents; Bacteremia; Braces; Cattle; Combined Modality Therapy; Disciti | 2013 |
Occurrence and antibacterial susceptibility pattern of bacterial pathogens isolated from diarrheal patients in Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacillus cereus; Cef | 2016 |
Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cataract E | 2008 |
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Discitis; Drug Monitoring; Female; Follow-Up | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinol | 2010 |
Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2010 |
Liver abscess and empyema due to Lactococcus lactis cremoris.
Topics: Adult; Anti-Bacterial Agents; Cefotaxime; Drainage; Empyema; Gram-Positive Bacterial Infections; Hum | 2010 |
Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Enterococcus fa | 2011 |
Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resist | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Di | 2013 |
Polymicrobial keratitis secondary to Burkholderia ambifaria, enterococcus, and staphylococcus aureus in a patient with herpetic stromal keratitis.
Topics: Amikacin; Burkholderia; Burkholderia Infections; Corneal Stroma; Drug Therapy, Combination; Enteroco | 2003 |
Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis.
Topics: Adult; Aged; Analysis of Variance; Cefotaxime; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Urinary tract infection caused by Aerococcus viridans, a case report.
Topics: Aged; Aged, 80 and over; Bacteremia; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; | 2004 |
Kocuria kristinae infection associated with acute cholecystitis.
Topics: Acute Disease; Anti-Bacterial Agents; Cholecystitis; Gram-Positive Bacterial Infections; Humans; Lev | 2005 |
Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Escherichia coli Infec | 1989 |
[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Topics: Aged; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; | 2006 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinol | 2006 |
Infectious crystalline keratopathy caused by Gemella haemolysans.
Topics: Anti-Bacterial Agents; Cefuroxime; Colony Count, Microbial; Corneal Diseases; Drug Therapy, Combinat | 2007 |
Postoperative endophthalmitis caused by Bacillus cereus and Chlamydia trachomatis.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Bacillus cereus; Bacteri | 2007 |
Gemella haemolysans infectious crystalline keratopathy.
Topics: Anti-Bacterial Agents; Cefuroxime; Colony Count, Microbial; Corneal Diseases; Drug Therapy, Combinat | 2008 |
Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Biological Availability; Disease Progression; Endo | 2008 |
Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.
Topics: Evaluation Studies as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positi | 1993 |
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquino | 1993 |
Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice.
Topics: Ampicillin; Animals; Cefozopran; Ceftazidime; Cephalosporins; Cilastatin; Enterococcus faecalis; Fem | 1997 |
Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Dermatitis; Drug Resistance, Microbial; | 1998 |
In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Corynebacterium; Drug Resistance, Microbial; Fluoroquinolones; | 1998 |
Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Amoxicillin; Anti-Bacterial Agents; Bisexuality; Black | 1998 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu | 1998 |
In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against Micrococcus species and Stomatococcus mucilaginosus isolated from healthy subjects and neutropenic patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Human | 1998 |
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Ciprofloxacin; Fluoroquinolones; Gram-Negat | 1999 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinol | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gr | 2000 |
Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cornea; Corneal Ulcer; Drug R | 2000 |
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxon | 2000 |
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Drug Resistance, Microbial; Fever; Gram | 2001 |
Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacterial | 2001 |
Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Cefazolin; Cefotaxime; Ce | 2002 |